Trial Profile
The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: an unblinded, multicentre, randomised controlled trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2018
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms MIDAs
- 13 Oct 2015 Results published in the Antiviral Therapy
- 13 Oct 2015 Primary endpoint (Vitamin D levels endpoint is change in 25(OH) Vitamin D) has been met as per results published in the Antiviral Therapy
- 29 Aug 2014 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.